Myrbetriq – sold as Betanis and Betmiga in some markets – is an extended-release selective beta3-adrenoceptor agonist therapy used to treat overactive bladder with symptoms of urinary ...
In 2014 Myrbetriq entered the extremely crowded, commoditized market of products with the intent to become leader in the Overactive Bladder (OAB) treatment category. Using TV, social media, apps and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results